Study provides further evidence for pre-surgery immune checkpoint inhibitors in operable skin cancer Giving the combination of immune checkpoint inhibitors relatlimab and nivolumab to patients with stage III melanoma before surgery was safe and completely cleared all viable tumor in 57% of patients in […]
